ECT vs Clozapine: LTE in Asian Journal of Psychiatry
Out on PubMed, from authors in India, is this LTE:
Is ECT better than clozapine for treatment-resistant schizophrenia?
This is a thoughtful LTE that is mostly about methodological issues with the Mishra study in Schizophrenia Bulletin in 2022 (please see below).
Study results: The PANSS-T scores changes from baseline over the observation-points were significant in both M-ECT and clozapine groups (P < .001), with comparatively better reduction with M-ECT (P < .001). Similar trends were observed in PANSS subscales, CGI-SCH and GAF in both groups, with significantly better improvement with M-ECT over the study-period. After 24 weeks, there was significantly better perfusion with M-ECT in bilateral prefrontal and temporal cortices (P < .05). With M-ECT, a positive correlation was found between changes in PANSS-P scores and left-lateral Temporal cortical perfusion (r = .465, P = .017).
Conclusions: Acute followed by M-ECT was more effective than clozapine over 6 months in reducing the positive and negative symptoms, general psychopathology, illness-severity, and improving the global functionality in TRS [clinicaltrials.gov: NCT03807882].
This is a very important topic, given that ECT is woefully underutilized for psychosis in the US. Hopefully, future ISEN and APA meetings will give this the attention it deserves.
ReplyDelete